-2%
dizziness and increased thirstiness.
Pregnancy & Lactation
There are no adequate and well-controlled studies of Empagliflozin in pregnant women. Empagliflozin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known if Empagliflozin is excreted in human milk. It is not recommended when breastfeeding.
Precautions & Warnings
Assessment of renal function is recommended prior to initiation of Ardance and periodically thereafter. Ardance should not initiated in patients with an eGFR less than 45 ml/min/1.73 m2. No dose adjustment is needed in patients with an eGFR greater than or equal to 45 ml/min/1.73 m2.
Overdose Effects
In the event of an overdose with Ardance the usual supportive measures (e.g., remove unabsorbed material from the gastrointestinal tract, perform clinical monitoring, and institute supportive treatment) should be employed. Removal of Ardance by hemodialysis has not been studied.
Therapeutic Class
Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
Storage Conditions
Keep in a cool & dry place (below 30° C), protected from light & moisture. Keep out of the reach of children.